

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Growth 2025-2031

<https://marketpublishers.com/r/GB94CB32897EN.html>

Date: May 2025

Pages: 96

Price: US\$ 3,660.00 (Single User License)

ID: GB94CB32897EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global FIB-SEM System market size is predicted to grow from US\$ 644 million in 2025 to US\$ 910 million in 2031; it is expected to grow at a CAGR of 5.9% from 2025 to 2031.

The FIB-SEM system is an electron microscope system that integrates focused electron beams and scanning ion beams. Focused ion beams can be used for micro processing of samples, scanning electron beams can be used for micro imaging and 'two-dimensional' characterization analysis of sample surface morphology, and real-time observation of the FIB processing process. Therefore, the FIB-SEM system can achieve fixed-point etching, deposition, cross-sectional cutting, TEM electron microscopy sample preparation, and micro/nano device preparation of samples Circuit repair, 3D structural characterization, etc.

Global key players of FIB-SEM System include Thermo Fisher Scientific Hitachi and Zeiss, etc. The top three players hold a share over 85%. Japan is the largest market. In terms of product type, Ga Ion Source is the largest segment, occupied for a share of 95%, and in terms of application, Material Science has a share about 40 percent.

Analysis of FIB-SEM system market drivers

1. Demand for semiconductor technology iteration

Advanced process node promotion:

3nm/2nm chip process requires atomic-level defect detection, and FIB-SEM supports nanoscale circuit editing and material composition analysis (such as EDS/EBSD integration) to help improve yield.

3D packaging technology (such as Chiplet) relies on FIB-SEM for through-silicon via (TSV) cross-sectional analysis and interface defect positioning.

Semiconductor material innovation:

The microstructure research of third-generation semiconductors (GaN, SiC) and two-dimensional materials (graphene) requires FIB-SEM to achieve atomic-level resolution imaging (

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Sales 2020-2031
- 2.1.2 World Current & Future Analysis for PARP (Poly ADP-Ribose Polymerase) Inhibitor by Geographic Region, 2020, 2024 & 2031

- 2.1.3 World Current & Future Analysis for PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country/Region, 2020, 2024 & 2031

2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Type

- 2.2.1 Lynparza
- 2.2.2 Zejula
- 2.2.3 Rubraca
- 2.2.4 Talzenna
- 2.2.5 Other

2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type

- 2.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2020-2025)
- 2.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Type (2020-2025)
- 2.3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Type (2020-2025)

2.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Application

- 2.4.1 Ovarian Cancer
- 2.4.2 Breast Cancer
- 2.4.3 Other

2.5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application

2.5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Market Share by Application (2020-2025)

2.5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Application (2020-2025)

2.5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Breakdown Data by Company

3.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Sales by Company (2020-2025)

3.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Company (2020-2025)

3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Revenue by Company (2020-2025)

3.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2020-2025)

3.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Company (2020-2025)

3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Company

3.4 Key Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Location Distribution

3.4.2 Players PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITOR BY GEOGRAPHIC REGION

4.1 World Historic PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Geographic Region (2020-2025)

4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Sales by

Geographic Region (2020-2025)

4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Revenue by Geographic Region (2020-2025)

4.2 World Historic PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country/Region (2020-2025)

4.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Sales by Country/Region (2020-2025)

4.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Revenue by Country/Region (2020-2025)

4.3 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth

4.4 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth

4.5 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth

4.6 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth

5 AMERICAS

5.1 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country

5.1.1 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2025)

5.1.2 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2020-2025)

5.2 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020-2025)

5.3 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2020-2025)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region

6.1.1 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2020-2025)

6.1.2 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2020-2025)

6.2 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020-2025)

6.3 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application

(2020-2025)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country

7.1.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country
(2020-2025)

7.1.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country
(2020-2025)

7.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020-2025)

7.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application
(2020-2025)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country

8.1.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by
Country (2020-2025)

8.1.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by
Country (2020-2025)

8.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type
(2020-2025)

8.3 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by
Application (2020-2025)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor

10.3 Manufacturing Process Analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor

10.4 Industry Chain Structure of PARP (Poly ADP-Ribose Polymerase) Inhibitor

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors

11.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customer

12 WORLD FORECAST REVIEW FOR PARP (POLY ADP-RIBOSE POLYMERASE) INHIBITOR BY GEOGRAPHIC REGION

12.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Forecast by Region

12.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Region (2026-2031)

12.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Revenue Forecast by Region (2026-2031)

12.2 Americas Forecast by Country (2026-2031)

12.3 APAC Forecast by Region (2026-2031)

12.4 Europe Forecast by Country (2026-2031)

12.5 Middle East & Africa Forecast by Country (2026-2031)

12.6 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Type

(2026-2031)

12.7 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Application
(2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 AstraZeneca

13.1.1 AstraZeneca Company Information

13.1.2 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications

13.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)

13.1.4 AstraZeneca Main Business Overview

13.1.5 AstraZeneca Latest Developments

13.2 Tesaro

13.2.1 Tesaro Company Information

13.2.2 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications

13.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)

13.2.4 Tesaro Main Business Overview

13.2.5 Tesaro Latest Developments

13.3 Merck & Co

13.3.1 Merck & Co Company Information

13.3.2 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications

13.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)

13.3.4 Merck & Co Main Business Overview

13.3.5 Merck & Co Latest Developments

13.4 Clovis Oncology

13.4.1 Clovis Oncology Company Information

13.4.2 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications

13.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)

13.4.4 Clovis Oncology Main Business Overview

13.4.5 Clovis Oncology Latest Developments

13.5 Pfizer

- 13.5.1 Pfizer Company Information
- 13.5.2 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications
- 13.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
- 13.5.4 Pfizer Main Business Overview
- 13.5.5 Pfizer Latest Developments
- 13.6 GSK
 - 13.6.1 GSK Company Information
 - 13.6.2 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications
 - 13.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.6.4 GSK Main Business Overview
 - 13.6.5 GSK Latest Developments
- 13.7 Zai Lab
 - 13.7.1 Zai Lab Company Information
 - 13.7.2 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications
 - 13.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.7.4 Zai Lab Main Business Overview
 - 13.7.5 Zai Lab Latest Developments
- 13.8 Hengrui Medical
 - 13.8.1 Hengrui Medical Company Information
 - 13.8.2 Hengrui Medical PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications
 - 13.8.3 Hengrui Medical PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.8.4 Hengrui Medical Main Business Overview
 - 13.8.5 Hengrui Medical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)
- Table 2. PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)
- Table 3. Major Players of Lynparza
- Table 4. Major Players of Zejula
- Table 5. Major Players of Rubraca
- Table 6. Major Players of Talzenna
- Table 7. Major Players of Other
- Table 8. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020-2025) & (K Units)
- Table 9. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2020-2025)
- Table 10. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2020-2025) & (\$ million)
- Table 11. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2020-2025)
- Table 12. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Type (2020-2025) & (USD/Unit)
- Table 13. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale by Application (2020-2025) & (K Units)
- Table 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Market Share by Application (2020-2025)
- Table 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2020-2025) & (\$ million)
- Table 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2020-2025)
- Table 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Application (2020-2025) & (USD/Unit)
- Table 18. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company (2020-2025) & (K Units)
- Table 19. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Company (2020-2025)
- Table 20. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2020-2025) & (\$ millions)

Table 21. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Company (2020-2025)

Table 22. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Company (2020-2025) & (USD/Unit)

Table 23. Key Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Producing Area Distribution and Sales Area

Table 24. Players PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered

Table 25. PARP (Poly ADP-Ribose Polymerase) Inhibitor Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 26. New Products and Potential Entrants

Table 27. Market M&A Activity & Strategy

Table 28. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Geographic Region (2020-2025) & (K Units)

Table 29. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share Geographic Region (2020-2025)

Table 30. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 31. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Geographic Region (2020-2025)

Table 32. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country/Region (2020-2025) & (K Units)

Table 33. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country/Region (2020-2025)

Table 34. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country/Region (2020-2025) & (\$ millions)

Table 35. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country/Region (2020-2025)

Table 36. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2025) & (K Units)

Table 37. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2020-2025)

Table 38. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2020-2025) & (\$ millions)

Table 39. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020-2025) & (K Units)

Table 40. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2020-2025) & (K Units)

Table 41. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2020-2025) & (K Units)

Table 42. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2020-2025)

Table 43. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2020-2025) & (\$ millions)

Table 44. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020-2025) & (K Units)

Table 45. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2020-2025) & (K Units)

Table 46. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2025) & (K Units)

Table 47. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2020-2025) & (\$ millions)

Table 48. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020-2025) & (K Units)

Table 49. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2020-2025) & (K Units)

Table 50. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2025) & (K Units)

Table 51. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2020-2025)

Table 52. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020-2025) & (K Units)

Table 53. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2020-2025) & (K Units)

Table 54. Key Market Drivers & Growth Opportunities of PARP (Poly ADP-Ribose Polymerase) Inhibitor

Table 55. Key Market Challenges & Risks of PARP (Poly ADP-Ribose Polymerase) Inhibitor

Table 56. Key Industry Trends of PARP (Poly ADP-Ribose Polymerase) Inhibitor

Table 57. PARP (Poly ADP-Ribose Polymerase) Inhibitor Raw Material

Table 58. Key Suppliers of Raw Materials

Table 59. PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List

Table 60. PARP (Poly ADP-Ribose Polymerase) Inhibitor Customer List

Table 61. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Region (2026-2031) & (K Units)

Table 62. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 63. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Country (2026-2031) & (K Units)

Table 64. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 65. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Region (2026-2031) & (K Units)

Table 66. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Annual Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 67. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Country (2026-2031) & (K Units)

Table 68. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 69. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Country (2026-2031) & (K Units)

Table 70. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 71. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Type (2026-2031) & (K Units)

Table 72. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Type (2026-2031) & (\$ millions)

Table 73. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Application (2026-2031) & (K Units)

Table 74. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Application (2026-2031) & (\$ millions)

Table 75. AstraZeneca Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 76. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications

Table 77. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. AstraZeneca Main Business

Table 79. AstraZeneca Latest Developments

Table 80. Tesaro Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 81. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications

Table 82. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. Tesaro Main Business

Table 84. Tesaro Latest Developments

Table 85. Merck & Co Basic Information, PARP (Poly ADP-Ribose Polymerase)

Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 86. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications

Table 87. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. Merck & Co Main Business

Table 89. Merck & Co Latest Developments

Table 90. Clovis Oncology Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 91. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications

Table 92. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 93. Clovis Oncology Main Business

Table 94. Clovis Oncology Latest Developments

Table 95. Pfizer Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 96. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications

Table 97. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 98. Pfizer Main Business

Table 99. Pfizer Latest Developments

Table 100. GSK Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 101. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications

Table 102. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 103. GSK Main Business

Table 104. GSK Latest Developments

Table 105. Zai Lab Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 106. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications

Table 107. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 108. Zai Lab Main Business

Table 109. Zai Lab Latest Developments

Table 110. Hengrui Medical Basic Information, PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base, Sales Area and Its Competitors

Table 111. Hengrui Medical PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolios and Specifications

Table 112. Hengrui Medical PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 113. Hengrui Medical Main Business

Table 114. Hengrui Medical Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of PARP (Poly ADP-Ribose Polymerase) Inhibitor
- Figure 2. PARP (Poly ADP-Ribose Polymerase) Inhibitor Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate 2020-2031 (K Units)
- Figure 7. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate 2020-2031 (\$ millions)
- Figure 8. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)
- Figure 9. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country/Region (2024)
- Figure 10. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country/Region (2020, 2024 & 2031)
- Figure 11. Product Picture of Lynparza
- Figure 12. Product Picture of Zejula
- Figure 13. Product Picture of Rubraca
- Figure 14. Product Picture of Talzenna
- Figure 15. Product Picture of Other
- Figure 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type in 2025
- Figure 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2020-2025)
- Figure 18. PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumed in Ovarian Cancer
- Figure 19. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Ovarian Cancer (2020-2025) & (K Units)
- Figure 20. PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumed in Breast Cancer
- Figure 21. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Breast Cancer (2020-2025) & (K Units)
- Figure 22. PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumed in Other
- Figure 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Other (2020-2025) & (K Units)
- Figure 24. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Market Share by

Application (2024)

Figure 25. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application in 2025

Figure 26. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Company in 2025 (K Units)

Figure 27. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Company in 2025

Figure 28. PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company in 2025 (\$ millions)

Figure 29. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Company in 2025

Figure 30. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Geographic Region (2020-2025)

Figure 31. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Geographic Region in 2025

Figure 32. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2020-2025 (K Units)

Figure 33. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue 2020-2025 (\$ millions)

Figure 34. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2020-2025 (K Units)

Figure 35. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue 2020-2025 (\$ millions)

Figure 36. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2020-2025 (K Units)

Figure 37. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue 2020-2025 (\$ millions)

Figure 38. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2020-2025 (K Units)

Figure 39. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue 2020-2025 (\$ millions)

Figure 40. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country in 2025

Figure 41. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2020-2025)

Figure 42. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2020-2025)

Figure 43. Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2020-2025)

Figure 44. United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2020-2025 (\$ millions)

Figure 45. Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2020-2025 (\$ millions)

Figure 46. Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2020-2025 (\$ millions)

Figure 47. Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2020-2025 (\$ millions)

Figure 48. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region in 2025

Figure 49. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2020-2025)

Figure 50. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2020-2025)

Figure 51. APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2020-2025)

Figure 52. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2020-2025 (\$ millions)

Figure 53. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2020-2025 (\$ millions)

Figure 54. South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2020-2025 (\$ millions)

Figure 55. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2020-2025 (\$ millions)

Figure 56. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2020-2025 (\$ millions)

Figure 57. Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2020-2025 (\$ millions)

Figure 58. China Taiwan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth 2020-2025 (\$ millions)

Figure 59. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country in 2025

Figure 60. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2020-2025)

Figure 61. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2020-2025)

Figure 62. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2020-2025)

Figure 63. Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth

2020-2025 (\$ millions)

Figure 64. France PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth
2020-2025 (\$ millions)

Figure 65. UK PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth
2020-2025 (\$ millions)

Figure 66. Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth
2020-2025 (\$ millions)

Figure 67. Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth
2020-2025 (\$ millions)

Figure 68. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales
Market Share by Country (2020-2025)

Figure 69. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales
Market Share by Type (2020-2025)

Figure 70. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales
Market Share by Application (2020-2025)

Figure 71. Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth
2020-2025 (\$ millions)

Figure 72. South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue
Growth 2020-2025 (\$ millions)

Figure 73. Israel PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth
2020-2025 (\$ millions)

Figure 74. Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth
2020-2025 (\$ millions)

Figure 75. GCC Countries PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue
Growth 2020-2025 (\$ millions)

Figure 76. Manufacturing Cost Structure Analysis of PARP (Poly ADP-Ribose
Polymerase) Inhibitor in 2025

Figure 77. Manufacturing Process Analysis of PARP (Poly ADP-Ribose Polymerase)
Inhibitor

Figure 78. Industry Chain Structure of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Figure 79. Channels of Distribution

Figure 80. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market
Forecast by Region (2026-2031)

Figure 81. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market
Share Forecast by Region (2026-2031)

Figure 82. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share
Forecast by Type (2026-2031)

Figure 83. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market
Share Forecast by Type (2026-2031)

Figure 84. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share Forecast by Application (2026-2031)

Figure 85. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share Forecast by Application (2026-2031)

I would like to order

Product name: Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/GB94CB32897EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB94CB32897EN.html>